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Abstract
Objective: Lung transplantation has become an established treatment option for end-stage pulmonary diseases. However, outcome depends on
preoperative condition and co-morbidity. Furthermore, perioperative blood-product use is known to be associated with worse outcome even in
transplant surgery. We investigated the impact of poor preoperative right-ventricular function and blood-product use on outcome after lung
transplantation. Methods: The medical records of 169 lung-transplant recipients from 1996 to 2006 were examined. Duration of hospital stay,
hours on mechanical ventilation, duration of stay in the intensive care unit, perioperative complications, death during hospital stay, and long-
term survival were recorded. These outcome parameters were analyzed regarding coherence with right-ventricular function and the
perioperative administration of crystalloids, colloids, allogeneic red blood cells, fresh frozen plasma, and platelets. Results: Patients with
poor preoperative right-ventricular function had a significant increase in postoperative hours on ventilation ( p = 0.005), intensive care stay
( p = 0.003), and in-hospital death (p = 0.012). The hours on ventilation increased also with high intra-operative fluid administration (p = 0.026).
Blood-product use was associated with prolonged mechanical ventilation and intensive care stay. After multivariate analysis, transfusion of
platelets ( p = 0.022) was an independent prognostic factor for in-hospital death. Hours of mechanical ventilation was the only independent
prognostic factor for long-termmortality ( p = 0.014). Conclusions: Perioperative transfusion of platelets is an independent prognostic factor for
perioperative mortality. Furthermore, the study indicated that poor preoperative right-ventricular function might worsen perioperatively after
lung transplantation. Therefore, pre-transplant treatment of pulmonary hypertension to protract right-ventricular failure and a restrictive use of
allogeneic blood products may be options to improve outcome.
# 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Almost 3 decades have passed since the first successful
clinical lung transplant was performed in 1983. Over the
intervening years, lung transplantation has become the
preferred treatment option for a variety of end-stage
pulmonary diseases. Remarkable progress has been made
in the field through refinement of surgical technique and
enhanced understanding of transplant immunology and
microbiology, improved intensive post-transplant patient
care and advancement of anesthetic and critical-care
management. However, outcome is different for different
indications and co-morbidity [1]. There were several§ Funding: Support was provided solely from institutional sources.
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doi:10.1016/j.ejcts.2010.07.040patients with poor preoperative right-ventricular function
(PRVF) and fatal outcome in our lung-transplant program
[2]. PRVF has not been studied under this perspective,
which disposed us to investigate the impact of PRVF on
perioperative outcome in lung transplantation. Periopera-
tive blood-product use is known to be associated with
worse outcome after general, cardiac, trauma and liver
transplant surgery [3—6]. We, therefore, also investigated
the impact of blood-product use in lung transplantation.
2. Methods
Ethical Committee approval was obtained for an
anonymized data acquisition. The medical records of all
lung-transplant recipients from 1996 to 2006 were
examined. The following outcome parameters were
recorded: duration of hospital stay, hours on mechanical
ventilation, duration of stay in the intensive care uniturgery. Published by Elsevier B.V. All rights reserved.
M.P. Zalunardo et al. / European Journal of Cardio-thoracic Surgery 39 (2011) 538—542 539
Table 1. Patient characteristics and preoperative diagnosis.
Age (year/range) 42  16/12;68
Height (cm/range) 168  10/133;191
Weight (kg/range) 57  16/24;122
Gender (m/f) 92/77
Pre-mPAP (mm Hg/range) 31  14/10;74
Post-mPAP (mm Hg/range) 22  6/6;40
EMP, n (%) 87 (51)
PLD, n (%) 36 (21)
CF, n (%) 32 (19)
PH, n (%) 10 (6)
OTH, n (%) 4 (3)
Values are mean  SD. Pre-mPP: preoperative mean pulmonary artery pres-
sure after anesthesia induction; post-mPP: immediate postoperative mean
pulmonary artery pressure prior to the transfer to the ICU; preoperative
diagnosis — EMP: emphysema; PLD: parenchymal lung disorders; CF: cystic
fibrosis; PH: primary pulmonary hypertension; OTH: other diseases.
Table 2. In-hospital death and complications.
Deatha, n (%) 19 (11)
Severe bacterial infection, n (%) 3 (2)
Seropneumothorax, n (%) 1 (0.6)
Dehiscent sternum, n (%) 1 (0.6)
Encephalopathy, n (%) 1 (0.6)
Muscular weakness, n (%) 1 (0.6)
Quantity and sort of complications and occurrence of death during the hospital
stay.
a Causes of in-hospital death (n): multi-organ failure (2), multi-organ
failure with preceding right heart failure (2), hyperammonemia (3), sepsis
(3), right heart failure (2), cerebrovascular lesion (2), esophageal perforation
(1), duodenal and colorectal perforation (1), unknown (3).(ICU), perioperative complications including death during
hospital stay and long-term mortality. These outcome
parameters were correlated with poor versus good PRVF,
and perioperative fluid and blood-product administration,
that is, Ringer’s lactate solution, hydroxyethyl starch,
gelatin solution, allogeneic red blood cells (RBCs), fresh
frozen plasma (FFP) and platelets. Between 1996 and 2006,
blood component therapy at our institution was according
to the American Society of Anesthesiologists (ASA) guide-
lines, that is, in situations of massive bleeding, RBCs were
given at hemoglobin concentrations between 6 g dl1 and
10 g dl1, FFP at prothrombin time (PT) or partial
thromboplastin time (PTT) >1.5 times normal and plate-
lets between 50 and 100  109 l1 [7]. All echocardio-
graphic studies were performed by a specially trained
cardiologist. The studies of all lung-transplant candidates
were inspected and corrected at best by the head of the
echocardiography lab. Prior to the year 2000, right-
ventricular function had been described only by a
qualitative report (sufficient or poor function). Thereafter,
tricuspid annular motion (TAM) and fractional area change
(fac) have been introduced in echocardiography as
validated indicators for right-ventricular function. The
cut-off values for poor right-ventricular function were TAM
17 mm; fac 25%. Patients with incomplete data were
excluded.
3. Statistical analysis
All outcome parameters have been tested for significant
correlation with poor or good right-ventricular function
and with perioperative fluid and blood-product adminis-
tration. Hours on ventilation, intensive care stay and
hospital stay have been analyzed with the Mann—Whitney
U-Test, and perioperative complications and death with
Fisher’s exact test. All outcome parameters with signifi-
cance p 0.07 for univariate analyses have been further
tested for independent impact with stepwise logistic
regression. Long-term survival was analyzed using
Kaplan—Meier curves. Groups were compared using the
log-rank test. Multivariate analysis was performed using
stepwise Cox regression. To evaluate the use of cardio-
pulmonary bypass (CPB) as a possible confounding factor,
we analyzed the impact of CPB on in-hospital and long-
term survival and on platelet administration.
4. Results
As many as 44 of 213 patients were excluded due to
incompleteness of essential data. The medical records of 169
patients were analyzed. Patient characteristics are shown in
Table 1. Emphysema, parenchymal lung diseases and cystic
fibrosis were the most frequent diagnoses or indications for
lung transplantation. A total of 19 patients died during
hospital stay and seven had severe complications. Table 2
summarizes perioperative complications. Table 3 shows
absolute numbers of in-hospital survivors and deaths relating
to the investigated risk factors.5. Univariate analyses
Patients with poor PRVF had significantly augmented
postoperative ventilation time ( p = 0.005), prolonged inten-
sive care stay ( p = 0.003) and higher risk of in-hospital death
( p = 0.012). Patients with greater total intra-operative fluid
volume administration, that is, blood products, crystalloids
and colloids, were longer on mechanical ventilation
( p = 0.026). However, the individual administration of Ring-
er’s lactate solution, hydroxyethyl starch and gelatin solution
showed no significant effect. Last but not the least, blood-
product use, that is, use of RBCs, FFP or platelets was
associated with a significantly prolonged ventilation time and
intensive care stay (Table 4). The use of CPB had no
significant impact on in-hospital and long-term survival. The
duration of CPB and the total amount of the heparin dose
given during bypass were similar in those patients who
received platelets and those who did not. The length of CPB
and the dose of heparin had no impact on platelet
administration (Table 5).
6. Multivariate analyses
Intra-operative transfusion of platelets ( p = 0.022) was an
independent prognostic factor for death during hospital stay,
whereas poor PRVF barely missed statistical significance
( p = 0.053; Table 4). Hours of ventilation was the only
independent prognostic factor for long-term mortality
( p = 0.014), whereas platelet transfusion and poor PRVF
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Table 3. Prognostic factors related to in-hospital survivors and deaths.
Total In-hospital In-hospital survivors Deaths
Poor PRVF 14/150a (8%) 9/131a (7%) 5/17a (29%)
PRBC 113/169 (67%) 96/148 (65%) 15/19 (79%)
FFP 102/169 (60%) 86/148 (58%) 14/19 (74%)
Platelets 20/169 (12%) 13/148 (9%) 6/19 (32%)
TFV 5.3/0;22.8 5.0/0;22.8 6.0/0;21.2
HOV 14/4;5208 12/4;1488 32/6;5208
PRVF: preoperative right-ventricular function.
a Data of 19 patients not analyzable due to incomplete preoperative
echocardiographic report. PBRC: packed red blood cells; FFP: fresh frozen
plasma; TFV: total intra-operative fluid volume, including all blood products,
crystalloids and colloids: liters, median/range; HOV: hours of mechanical
ventilation: median/range.
Table 5. Impact of cardiopulmonary bypass on survival and platelet adminis-
tration.
No CPB CPB p-value
In-hospital deaths 10/114 (9%) 9/50 (18%) 0.089
5-year survival rate 0.71  0.04 0.64  0.07 0.55
In-hospital survivors In-hospital deaths p-value
Duration of CPBa 188 (81—390) 189 (81—297) 0.84
Heparinb 11250 (3000—27600) 14000 (3500—21600) 0.86
No platelets Platelets p-value
No CPB (n) 110 5 —
CPB (n) 36 15 —
Duration of CPBa 186 (81—390) 210 (81—358) 0.25
Heparinb 11500 (3000—27600) 16800 (3750—32000) 0.36
CPB: cardiopulmonary bypass. 5-year survival rate: estimate  standard error.
a Duration of cardiopulmonary bypass: minutes (range).
b Heparin: units (range).were not significant (Figs. 1 and 2). None of the other
univariate correlations remained statistically significant in
the stepwise logistic regression (Table 4).Table 4. Univariate and multivariate analysis.
Univariate analysis Multivariate analysis
Outcome parameter p-value p-value OR and HR* (95% CI)
Poor PRVF
HOV 0.005 ns
Intensive care stay 0.003 ns
Hospital stay ns
Complications ns
In-hospital survival 0.012 0.053 (ns) 4.0 (0.98—16.4)
Long-term survival ns
PRBC
HOV 0.030 ns
Intensive care stay 0.038 ns
Hospital stay ns
Complications ns
In-hospital survival ns
Long-term survival ns
FFP
HOV 0.001 ns
Intensive care stay 0.003 ns
Hospital stay ns
Complications ns
In-hospital survival 0.036 ns
Long-term survival ns
Platelets
HOV <0.001 ns
Intensive care stay 0.005 ns
Hospital stay ns
Complications ns
In-hospital survival 0.003 0.022 4.5 (1.25—16.3)
Long-term survival 0.054 (ns) ns
TFV
HOV 0.026 ns
Intensive care stay ns
Hospital stay ns
Complications ns
In-hospital survival ns
Long-term survival ns
HOV
Long-term survival 0.026 0.014 1.9* (1.14—3.2)
PRVF: preoperative right-ventricular function; PBRC: packed red blood cells;
FFP: fresh frozen plasma; TFV: total intra-operative fluid volume, including all
blood products, crystalloids and colloids; HOV: hours of mechanical ventila-
tion; OR: odds ratio; HR: hazard ratio after stepwise Cox regression; CI:
confidence interval. All outcome parameters with statistical significance
p  0.07 for univariate analyses have been further analyzed with stepwise
logistic regression to show independent impact. Long-term survival was ana-
lyzed using Kaplan—Meier curves. ns: not significant ( p > 0.05).7. Discussion
In times of organ shortage, risk factors for poor outcome
are important indicators, which may have an impact on both
the evaluation process of the transplant candidate and the
treatment concepts during the time on the waiting list. This
study indicates that poor PRVF may be an independent risk
factor for fatal outcome, which confirms our impression from
clinical practice. Preoperative pulmonary hypertension
increases mortality after lung, but also heart, kidney and
liver transplantation [1,8—10]. This applies not only for lung-
transplant recipients with primary pulmonary hypertension,
but also for patients with other indications for lung
transplantation such as idiopathic pulmonary fibrosis and
cystic fibrosis [11,12]. This corresponds to the experience of
our and other lung-transplant programs [2,13,14]. Chronic
pulmonary hypertension leads to right-ventricular failure in
the majority of cases, even though specific treatment may
prolong this process [15]. Therefore, and with regard to the
study results concerning poor PRVF, the treatment of
[()TD$FIG]
Fig. 1. Cumulative survival of lung transplant patients with or without poor
preoperative right-ventricular function (PRVF).
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Fig. 2. Cumulative survival of lung transplant patients with or without platelet
transfusion.pulmonary hypertension during the time on the waiting list
should be considered as an option to delay the development
of right-ventricular failure, which may improve outcome.
Several cases where pulmonary hypertension was success-
fully treated have been published in liver transplantation
[16,17]. Although the pathogenesis and classification of
pulmonary hypertension may be different for liver and lung
transplantation and the therapeutic options and probabilities
of success may differ [18], there is no evidence by now, that
treatment of pulmonary hypertension in lung-transplantation
candidates may not improve perioperative outcome. How-
ever, the results of this study should be confirmed with
further preferably prospective, randomized and controlled
investigations.
This study additionally shows that the transfusion of
platelets is correlated with significantly compromised
survival during hospital stay. This may seem unexpected
at first sight, all the more so as transfusion of FFP and RBCs
are known for this adverse effect [19], but have not shown
similar impact in lung transplantation. However, our findings
are consistent with those of Spiess et al., who showed that
platelet transfusion in the perioperative period of coronary
artery bypass graft (CABG) surgery is associated with
increased risk for serious adverse events such as infection,
stroke and death [20]. However, why did only platelets and
not also FFP or RBCs have this effect? The reason remained
unclear, as it is in our study. The design of their study, similar
to ours, was not randomized and controlled. By contrast,
McGrath et al. and Karkouti et al. found no increased risk
after platelet transfusion in cardiac surgery [21,22]. These
studies, as well, were only observational and were neither
randomized nor controlled. However, a prospective, con-
trolled study with or without blood-product use is difficult to
perform. A multicenter study from Mangano et al. of aspirin
use and mortality after CABG surgery showed that platelet
transfusion was significantly correlated with a six-fold
increase in mortality. Mortality was reduced in patients,
who received aspirin [23]. A further study of surgical ICUpatients with and without thrombocytopenia reported that
although platelet transfusion failed to restore a normal
platelet count, thrombocytopenia, and, presumably, plate-
let transfusion were associated with increased mortality
[24]. Last but not the least, Pereboom et al. and other
groups showed that platelet transfusion is an independent
risk factor for survival after orthotopic liver transplantation
due to platelet transfusion-related lung injury [5]. Lung-
transplant recipients might be at a similar risk, even though
there are different medical and procedural premises in liver
and lung transplantation. We also evaluated the use of CPB
as a relevant and possibly confounding factor for survival and
platelet administration [25]. The analysis did not show a
significant correlation. Thus, in view of the current
literature and the results of the present study, platelet
transfusion should be administered restrictively in lung
transplantation.
We also analyzed long-term mortality and found the
duration of mechanical ventilation to be the only indepen-
dent prognostic factor. However, we do not consider the
duration of mechanical ventilation causal for mortality
because weaning lung-transplant patients was attempted
on a daily basis, postoperatively. It is more likely that the
most severely ill were mechanically ventilated the longest,
some until death.
In summary, this study revealed platelet transfusion as a
significant and independent marker for perioperative mor-
tality, which supports the restricted and targeted use of
platelet transfusion in lung transplantation. Furthermore,
the study indicates that poor PRVF may compromise survival
after lung transplantation and preoperative treatment of
pulmonary hypertension to protract right-ventricular failure
may be a valuable option to improve outcome. These findings
need to be validated in randomized and controlled studies.
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